title: Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs.
abstract: Mucopolysaccharidosis VII (MPS VII) is a lysosomal storage disease due to deficient activity of beta-glucuronidase (GUSB) that results in accumulation of glycosaminoglycans in many organs. We have previously reported that neonatal intravenous injection of a gamma retroviral vector (RV) expressing canine GUSB resulted in transduction of hepatocytes, high levels of GUSB modified with mannose 6-phosphate in blood, and reduction in disease manifestations in the heart, bone, and eye. However, it was unclear if liver was the only site of expression, and the effect upon other organs was not assessed. We demonstrate here that blood cells from these RV-treated MPS VII dogs had substantial copies of RV DNA, and expressed the RNA at 2% of the level found in liver. Therefore, expression of GUSB in blood cells may synergize with uptake of GUSB from blood to reduce storage in organs. The RV-treated dogs had marked biochemical and pathological evidence of reduction in storage in liver, thymus, spleen, small intestines, and lung, and partial reduction of storage in kidney tubules. The brain had 6% of normal GUSB activity, and biochemical and pathological evidence of reduction in storage in neurons and other cell types. Thus, this neonatal gene therapy approach is effective and might be used in humans if it proves to be safe. Both secretion of enzyme into blood by hepatocytes, and expression in blood cells that migrate into organs, may contribute to correction of disease.
authors.affiliation: Department of Internal Medicine and Biochemistry, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.forename: Thomas M
authors.initials: TM
authors.lastname: O'Malley
authors.forename: Lingfei
authors.initials: L
authors.lastname: Xu
authors.forename: Charles
authors.initials: C
authors.lastname: Vite
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Patricia A
authors.initials: PA
authors.lastname: O'Donnell
authors.forename: N Matthew
authors.initials: NM
authors.lastname: Ellinwood
authors.forename: Mark E
authors.initials: ME
authors.lastname: Haskins
authors.forename: Katherine Parker
authors.initials: KP
authors.lastname: Ponder
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D004279:DNA, Viral / Q000378:metabolism; D004285:Dogs; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage; D005966:Glucuronidase / Q000097:blood* / Q000378:metabolism; D006025:Glycosaminoglycans / Q000378:metabolism* / Q000652:urine; D007275:Injections, Intravenous; D007962:Leukocytes / Q000378:metabolism*; D008099:Liver / Q000201:enzymology; D016538:Mucopolysaccharidosis VII / Q000097:blood / Q000628:therapy*; D012367:RNA, Viral / Q000378:metabolism; D012190:Retroviridae / Q000235:genetics; D013154:Spleen / Q000201:enzymology; D014018:Tissue Distribution; D014161:Transduction, Genetic; D001619:beta-N-Acetylhexosaminidases / Q000378:metabolism
chemical_list: D004279:DNA, Viral; D006025:Glycosaminoglycans; D012367:RNA, Viral; C020341:glucosaminoglycans; D005966:Glucuronidase; D001619:beta-N-Acetylhexosaminidases